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Tumour-to-tumour metastasis is an infrequent pathological phenomenon. Meningioma is the most common intracranial
tumour where metastatic deposits may be found, the majority of which arise from breast and lung cancers. We describe
an unusual case of occult pulmonary carcinoma metastasis into the intracranial meningioma. A 77-year old lady
presented with acutely deteriorating hemiparesis. Her previous medical history was unremarkable. Radiological imaging
revealed an expansive lesion, classified as meningioma, which was located parasagittally in the right premotor area. A
well-capsulated tumour attached to the dura was removed surgically. The pathological examination demonstrated a
mixture of angiomatous meningioma and pulmonary adenocarcinoma. Possible explanations for the development of a
composite tumour and pathophysiology are described.
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Tumours of non-neural origin, besides being aggressive
locally, metastasize frequently to the central nervous sys-
tem, and this represents a relatively common com-
plication of most cancers from elsewhere in the body,
including carcinoma of the lung and breast and malig-
nant melanoma [1–4]. On the other hand, primary brain
tumours that are also characterised by infiltrative growth
into the surrounding brain tissue are principally con-
fined to the central nervous system, and metastases of
these tumours to other locations are exceptional [4–6].
In addition to the rising incidence of primary and sec-
ondary brain tumours, tumour-to-tumour metastasis
may also be encountered in clinical practice [1, 3]. Al-
though these metastases from one tumour into another,
which is also called tumour-to-tumour phenomenon, are
a very rare pathological entity, they represent a well-
recognised phenomenon [2, 7, 8]. Meningiomas have been
described as the most frequent intracranial tumours to
host metastases, with cancers of breast and lung being the
most frequent primary sites [1, 3, 7, 9–12]. Other malig-
nancies have been only exceptionally found to metastasise
into meningioma, for example renal, genitourinary,* Correspondence: tvelnar@hotmail.com
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oma [1, 7, 11].
Clinically, a variety of signs and symptoms may occur
[5]. Epileptic seizures of different types, which may be
present in up to 85 % of patients, are one of the most
common symptoms. Others include headaches, nausea
and dizziness, sudden or insidious cognitive and mood
deteriorations, as well as sensory and motor distur-
bances in terms of localised or generalised limb weak-
ness and cranial nerve dysfunction due to affection of
eloquent brain zones or cranial nerves itself [1, 5, 6].
The differential diagnosis of such lesions may include a
primary cerebral malignancy or a metastatic tumour [1, 3].
Because metastases develop into meningiomas and may
simulate the metastatic disease both clinically and patho-
histologically, they present a unique differential diagnostic
dilemma [9].
Surgical excision is the principal form of treatment of
patients with a history of extracranial cancer although
stereotactic radiosurgery is becoming a desirable alterna-
tive therapeutic option, especially in eloquent areas of
the brain [13–15]. A concomitant solitary intracranial
mass must be preceded by radiographical determination
of the extent of the primary lesion and possible meta-
static deposits [13]. In order to diagnose these tumours,
various imaging modalities may be employed, includingis distributed under the terms of the Creative Commons Attribution 4.0
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aging (MRI) [8].
An unusual case of adenocarcinoma of the lung me-
tastasis into the intracranial meningioma in a 77-year
old lady is presented.
Case presentation
A 77-year old lady with a known expansive lesion of the
right frontal lobe was admitted to the department due to
a rapid deterioration of left-sided hemiparesis. She has
been followed up constantly at the neurosurgical out-
patient clinic as a result of an expansive lesion, radio-
logically characterised as meningioma. The lesion has
been known for many years, and according to radio-
logical imaging, it had been persistingly unchanged.
Until now, the woman was in a good medical condition
and did not report of any difficulties in relation to this
lesion. However, her neurological condition deteriorated
suddenly with weakness of the left limbs. At home, she
was walking with progressive difficulty, the gait was un-
stable and in a few hours, she was not able to stand and
walk any more. Additionally, she complained of frontal
headache and nausea. Neither loss of consciousness nor
seizures were reported by the relatives.
During a neurological examination, no consciousness
or cognitive deficits were found. Testing of cranial
nerves was normal. There was marked muscle weakness
of the left side, equally pronounced in the upper and
lower extremity. On the left, the muscle tone was
slightly lowered. In comparison with the right side, the
reflexes in the left upper and lower extremities were
weaker. Walking was not possible.
MRI of the head revealed progression of the tumour,
measuring 3 cm in diameter. It was located parasagittally
in the right premotor area, surrounded with an extensive
oedema, compressing the cortex. After contrast applica-
tion, it was enhanced homogenously (Fig. 1). Following
antioedematous therapy with intravenous injections ofa
Fig. 1 A sagittal T2-weighted spin echo image showing a cortical meningi
On T1-weighted spin echo image with contrast application (b), the tumourdexamethasone, the condition briefly improved but
worsened again despite further aggressive medicamen-
tous treatment. Surgery was indicated. A right parietal
parasagittal craniotomy was performed, nicely exposing
the oedematous brain tissue of premotor cortex with the
tumour, which was removed completely.
Histologically, the tumour was an angiomatous men-
ingioma. In the tumour mass, however, malignant tissue
arranged in cords and sheets and glandular formations
of atypical epithelial cells were present (Fig. 2). Malig-
nant cells were showing thyroid transcription factor-1
(TTF-1) nuclear immunoreactivity (Fig. 3). TTF-1 is
used as a marker to determine the origin of another
tumour from lung or thyroid. The frequency of TTF-1
immunoreactivity in extrapulmonary adenocarcinomas,
except the thyroid, is lower than 1 %, and the positivity
for TTF-1 may be interpreted as a definite evidence that
the tumour originates from the lung. Although the
neurological condition of the patient improved after the
operation, further diagnostics of the thorax revealed a
pulmonary lesion located in the left lung. Its histological
result was similar to the metastatic intracranial tumour.
No pulmonary symptoms were present, and excellent
performance state of the patient allowed appropriate
oncological therapy.
Discussion
Tumour-to-tumour metastasis is a rare entity, first
described in 1930 by Fried [16]. It denotes that one
primary tumour has metastatic foci of another primary
tumour in the same individual. This phenomenon is
uncommon, with less than 100 cases described in litera-
ture from its first report [17]. Any organ system may be
affected. Although every benign or malignant tumour
may be a recipient, the most common malignant tumour
as a recipient is the renal cell carcinoma and the most
common benign one is meningioma [1, 18–20]. The
donor neoplasm is most frequently breast carcinoma,b
oma in the motor area (arrow) surrounded by extensive oedema (a).
enhanced homogenously
Fig. 2 Histological sample of angiomatous meningioma with cords
and sheets of malignant cells from pulmonary carcinoma infiltrating
the meningioma tissue (haematoxylin and eosin staining, original
magnification ×200)
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sis from other primary tumours have been reported,
including renal and rarely prostate or genitourinary
cancers [19, 21, 22].
Campbell proposed strict criteria for this diagnosis in
1968, which are as follows: (I) existing more than one
primary tumour, (II) the recipient is a true neoplasm,
(III) the metastatic neoplasm is true metastasis with
evident growth in recipient tumour and (IV) exclusion
of the tumours that have metastasized to the lymphatic
system, where lymphoreticular malignant tumours al-
ready exist [23]. According to these, our patient meets
all the demanded criteria.
Tumour-to-tumour metastasis in the central nervous
system is even rarer [1]. Since the metastasis to lepto-
meningeal place is common, these metastatic foci canFig. 3 Histological sample with malignant cells showing TTF-1
nuclear immunoreactivity (coloured in brown) (TTF-1 stain, original
magnification ×40)arise next to the meningioma that may result in collision
of these two tumour types. In order to differentiate
tumour-to-tumour growth from collision tumours,
Pamphlett proposed other basic criteria [8]. For the
diagnosis of true tumour-to-meningioma metastasis the
following criteria should be considered: (I) the meta-
static foci should at least partially be enclosed by a rim
of histologically different host tumour tissue and (II) the
existing primary tumour should be proven and histologi-
cally compatible with metastasis. In our case, the lung
cancer metastasis to lung known meningioma fails the
first Campell’s and the second Pamphlett’s consideration,
although retrospectively it fulfils both [8, 23]. Our
patient was followed up regularly for years regarding
meningioma, which was not changing in size over the
time. A sudden enlargement of the meningioma due to
intratumoural bleeding and especially due to surround-
ing oedema causing the neurological deterioration of the
patient with subsequent surgical removal of the men-
ingioma, revealed the not known but existing cancer
disease. Histological specimen showed meningothelial
meningioma with clear inclusion foci of adenocar-
cinoma. Immunohistochemistry further revealed that the
origin could be the lung, which was later confirmed with
further imaging.
Meningiomas have been the most common intracranial
neoplasms to harbour metastasis, and the reason for a
cancer seeding into meningioma is not precisely known. It
is suggested that meningiomas, as generally slow growing
and indolent tumours, make a suitable destination for
cancer metastasis over a period of time due to the clinical
and biological characteristics, such as higher incidence
among intracranial neoplasms, hypervascularity, slow
growth, low metabolic activity and high collagen and lipid
content [7, 19, 21]. All of these characteristics create a
favourable, non-competitive environment which favours
this metastatic expansion [2, 3, 9]. Molecules involved in
the disruption of cellular adhesions and immunological in-
fluences may also contribute to this phenomenon [21, 24].
Frequently, tumour-to-tumour metastasis is seen in
the course of cancer disease and its treatment. It is very
unusual that the complications of the tumour-to-tumour
metastasis are the first sign of the cancer disease. Cli-
nically, a variety of signs and symptoms may occur [5].
Epileptic seizures of different types, which may be pre-
sent in up to 85 % of patients, are one of the most com-
mon symptoms. Others include headaches, nausea and
dizziness, sudden or insidious cognitive and mood dete-
riorations, as well as sensory and motor disturbances in
terms of localised or generalised limb weakness and
cranial nerve dysfunction due to affection of eloquent
brain zones or cranial nerves itself [1, 5, 6]. The dif-
ferential diagnosis of such lesions may include a pri-
mary cerebral malignancy or a metastatic tumour [1, 3].
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disease both clinically and pathohistologically, and
therefore, they present a unique differential diagnostic
dilemma [9].
Surgical excision is the principal form of treatment of
patients with a history of extracranial cancer and con-
comitant solitary intracranial mass and must be pre-
ceded by radiographical determination of the extent of
the primary lesion and possible metastatic deposits [13].
In order to diagnose these tumours, various imaging
modalities may be employed, including CT and MRI [8].
Limitations of these standard radiological imaging tech-
niques, which cannot reliably identify the presence of
metastasis within a meningioma, may be supplemented
with physiology-based neuroimaging methods, such as
perfusion MRI and MR spectroscopy. These may be
more useful in noninvasively differentiating tumour hist-
ology [17, 25]. Although MR spectroscopy is gaining
popularity, definitive results may be set only according
to the pathohistological findings [25, 26].
Alongside micro-neurosurgery, stereotactic radiosur-
gery is a desirable treatment modality [14, 27, 28]. As a
primary treatment, it is the most suitable in cases of
deep neurosurgically inaccessible or multiple lesions,
where conventional forms of radiotherapy by irradiating
the whole head are not appropriate due to the greater
risk of irradiation tissue damage [14, 28]. Besides tu-
mours, such as vestibular schwannomas, meningiomas,
certain primary brain tumours and brain metastases, ex-
amples include also arteriovenous malformations. Radio-
surgical treatment of lesions requires a source of high
energy rays and a method of applying the radiation in an
accurate way, conforming to the target volume thus pre-
serving the surrounding tissue [28–30]. In comparison
to micro-neurosurgery, the neurological deficits in pa-
tients treated with radiosurgical techniques tend to be
smaller, although technical limits and the risk of irradi-
ation damage to the brain do exist [14, 28].Conclusions
Tumour-to-tumour metastasis is a rare but well-known
event, especially in case of malignant tumours. Due to
high blood flow in the meningioma vessels, invasive pul-
monary carcinoma cells may easily be transported and
may survive in the meningioma tissue, with the tumour
microenvironment positively influencing the growth of
the implanted tumour cells.Consent
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